Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our lead asset ST-0529 is currently being evaluated in the AURORA (CYC-202) Study, a Phase 2b clinical trial for moderate to severe Ulcerative Colitis.